IPP Bureau

JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr
JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr

By IPP Bureau - August 08, 2024

Expect the international business including CDMO business to pick-up in the second half of the financial year

Apollo Clinic launches nationwide vaccination campaign to tackle monsoon illnesses
Apollo Clinic launches nationwide vaccination campaign to tackle monsoon illnesses

By IPP Bureau - August 08, 2024

Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics

Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion
Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion

By IPP Bureau - August 07, 2024

Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings

India emerging as world-class cost-effective healthcare destination and global pharma leader: Dr. Jitendra Singh
India emerging as world-class cost-effective healthcare destination and global pharma leader: Dr. Jitendra Singh

By IPP Bureau - August 07, 2024

He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries

Gland Pharma posts 16% revenue growth in Q1 FY25
Gland Pharma posts 16% revenue growth in Q1 FY25

By IPP Bureau - August 07, 2024

The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore

Lonza upgrades clinical manufacturing services at Bend site to include bottling and labeling capabilities
Lonza upgrades clinical manufacturing services at Bend site to include bottling and labeling capabilities

By IPP Bureau - August 07, 2024

Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment

Daiichi Sankyo and Merck enter into global agreement for MK-6070
Daiichi Sankyo and Merck enter into global agreement for MK-6070

By IPP Bureau - August 07, 2024

To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights

Sucralose safe to use in small doses; reveals MDRF study
Sucralose safe to use in small doses; reveals MDRF study

By IPP Bureau - August 07, 2024

Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers

Aster DM Healthcare launches Pediatric & Geriatric Emergency Departments at Aster MIMS, Calicut
Aster DM Healthcare launches Pediatric & Geriatric Emergency Departments at Aster MIMS, Calicut

By IPP Bureau - August 07, 2024

Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care

UK Relonchem receives marketing authorization for Levonorgestrel 1.5 mg Tablets
UK Relonchem receives marketing authorization for Levonorgestrel 1.5 mg Tablets

By IPP Bureau - August 06, 2024

Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA

Narayana Hrudayalaya posts Q1 FY25 consolidated PAT higher at Rs. 201.37 Cr
Narayana Hrudayalaya posts Q1 FY25 consolidated PAT higher at Rs. 201.37 Cr

By IPP Bureau - August 06, 2024

Narayana Hrudayalaya has reported total income of Rs. 1364.44 crores during the period ended June 30, 2024

Lupin completes  successful Phase 3 trials for Lucentis biosimilar
Lupin completes successful Phase 3 trials for Lucentis biosimilar

By IPP Bureau - August 06, 2024

The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU

Lupin receives USFDA approval for Prednisolone Acetate Ophthalmic Suspension USP
Lupin receives USFDA approval for Prednisolone Acetate Ophthalmic Suspension USP

By IPP Bureau - August 06, 2024

Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity

OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously
OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously

By IPP Bureau - August 06, 2024

Revolutionary technology will further boost OneSource’s scientific services offerings

Vijaya Diagnostic Centre reports Q1 FY25 consolidated PAT at Rs. 31.34 Cr
Vijaya Diagnostic Centre reports Q1 FY25 consolidated PAT at Rs. 31.34 Cr

By IPP Bureau - August 06, 2024

Vijaya Diagnostic Centre has reported total income of Rs. 159.78 crores during the quarter ended June 30, 2024

Latest Stories

Interviews

Packaging